Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Rhea-AI Summary

Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company focused on targeted radiotherapeutics for CNS cancers, has successfully addressed its Nasdaq listing compliance concerns. The company reported stockholders' equity of $3 million as of June 30, 2025, exceeding the minimum requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1).

This development follows a period of non-compliance identified on June 3, 2025, which led to a hearing before the Nasdaq Hearings Panel on July 15, 2025. The Panel granted Plus an extension to demonstrate compliance, and the company's recent Form 10-Q filing on August 14, 2025, confirms its return to compliance with the Equity Rule.

Positive

• Stockholders' equity increased to $3 million, exceeding Nasdaq's minimum requirement of $2.5 million
• Successfully maintained Nasdaq listing status by meeting compliance requirements
• Received extension from Nasdaq Hearings Panel to resolve compliance issues

Negative

• Previously fell below Nasdaq's minimum stockholders' equity requirement
• Company remains under Mandatory Panel Monitor through March 6, 2026

Insights

Financial Compliance Specialist

Plus Therapeutics regains Nasdaq compliance by exceeding minimum equity requirements, avoiding potential delisting.

Plus Therapeutics has successfully addressed a critical regulatory challenge by reporting $3 million in stockholders' equity as of June 30, 2025, exceeding Nasdaq's minimum requirement of $2.5 million. This achievement resolves a compliance issue that emerged on June 3 when Nasdaq notified the company it had fallen below the equity threshold based on March 31 figures.

The resolution comes after a formal hearing process with the Nasdaq Hearings Panel on July 15, which granted Plus an extension to demonstrate compliance. This represents a significant regulatory milestone for the clinical-stage pharmaceutical company, which focuses on developing targeted radiotherapeutics for central nervous system cancers.

Maintaining Nasdaq listing status is crucial for public biotech companies like Plus Therapeutics. A delisting would have severely restricted access to capital markets, reduced share liquidity, diminished institutional investor interest, and potentially triggered defaults on financial agreements. For clinical-stage companies without consistent revenue streams, maintaining market access is particularly vital for ongoing financing of research and development activities.

While the company has resolved this immediate compliance concern, investors should note that Plus remains under a Mandatory Panel Monitor through March 2026, indicating ongoing regulatory scrutiny of its financial position. The company now awaits official confirmation from Nasdaq that it has satisfied the equity requirement condition.

HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders’ equity of $3 million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”), as of June 30, 2025. The Equity Rule requires listed companies to maintain a minimum of $2.5 million in stockholders’ equity.

As previously reported, on June 3, 2025, the Nasdaq Listing Qualifications Department (the “Staff”) notified the Company that, as of March 31, 2025, the Company no longer satisfied the Equity Rule. Insofar as the Company was subject to a Mandatory Panel Monitor, as that term is defined under Nasdaq Listing Rule 5815(d)(4)(C), through March 6, 2026, with respect to the Equity Rule in particular, the Staff issued a delist determination following such non-compliance. On June 10, 2025, the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”), which stayed any further action by the Staff. The hearing was held on July 15, 2025.

As previously disclosed, on July 22, 2025, the Company was notified by Nasdaq that the Panel had granted the Company’s request for an extension to evidence compliance with the Equity Rule subject to the Company’s satisfaction of certain conditions.

As reflected in the Form 10-Q for the quarter ended June 30, 2025 filed August 14, 2025, the Company reported stockholders’ equity in excess of $2.5 million and therefore satisfied the Equity Rule as of June 30, 2025. The Company awaits Nasdaq’s confirmation that it has evidenced compliance with the Equity Rule.

About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.

Investor Contact
CORE IR
investor@plustherapeutics.com

FAQ

What is Plus Therapeutics' (PSTV) current stockholders' equity as of June 30, 2025?

Plus Therapeutics reported stockholders' equity of $3 million as of June 30, 2025, exceeding Nasdaq's minimum requirement of $2.5 million.

Why was Plus Therapeutics (PSTV) at risk of delisting from Nasdaq?

PSTV was at risk of delisting because it fell below Nasdaq's minimum requirement of $2.5 million in stockholders' equity as of March 31, 2025, violating Nasdaq Listing Rule 5550(b)(1).

When did Plus Therapeutics (PSTV) receive the Nasdaq extension to comply with equity requirements?

Plus Therapeutics received notification from Nasdaq on July 22, 2025 that the Panel had granted an extension to demonstrate compliance with the Equity Rule.

What is Plus Therapeutics' (PSTV) main business focus?

Plus Therapeutics is a clinical-stage pharmaceutical company that develops targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers.